{"id":22106,"date":"2026-02-23T16:44:09","date_gmt":"2026-02-23T16:44:09","guid":{"rendered":"https:\/\/www.europesays.com\/dk\/22106\/"},"modified":"2026-02-23T16:44:09","modified_gmt":"2026-02-23T16:44:09","slug":"novo-nordisk-stock-nvo-tumbles-in-worst-case-scenario-eli-lilly-nyselly-novo-nordisk-nysenvo","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/dk\/22106\/","title":{"rendered":"Novo Nordisk Stock (NVO) Tumbles in ‘Worst Case Scenario’ – Eli Lilly (NYSE:LLY), Novo Nordisk (NYSE:NVO)"},"content":{"rendered":"

Novo Nordisk AS (NYSE:<\/a>NVO<\/a>), once the darling of the pharmaceutical world, tumbled Monday as investors reacted to what analysts are calling a \u201cworst-case scenario.\u201d\u00a0<\/a><\/p>\n

Shares of Novo Nordisk stock plunged over 16% in morning trading, hitting a new 52-week low following disappointing results from the REDEFINE 4 Phase 3 clinical trial.\u00a0<\/p>\n

This latest blow brings the stock\u2019s one month decline to 36%.<\/p>\n

The Data Gap: CagriSema vs. Tirzepatide<\/p>\n

The 84-week trial involving 809 subjects failed to meet its primary endpoint of non-inferiority.\u00a0<\/p>\n

The efficacy results were clear:<\/p>\n

Adherent Treatment: Patients on CagriSema achieved a weight loss of 23.0%, compared to 25.5% for those on tirzepatide.<\/p>\n

Treatment Regimen Estimand: Under this measure, CagriSema showed 20.2% weight loss versus 23.6% for tirzepatide.<\/p>\n

While CagriSema maintained a safe and well-tolerated profile\u2014with gastrointestinal side effects consistent with the GLP-1 class\u2014the failure to match or beat Eli Lilly’s flagship drug shifted the competitive landscape.<\/p>\n

Expert Reactions and Market Implications<\/p>\n

The fallout from the REDEFINE 4 data was immediate.\u00a0<\/p>\n

According to a Zero Hedge report,<\/a> a Bloomberg Intelligence analyst noted that \u201cthis outcome is the worst-case scenario for Novo and heightens the need for M&A with Novo’s other GLP-1\/Amylin drug.\u201d<\/p>\n

Danske Bank Credit Research analyst Brian Borsting highlighted the strategic vulnerability.\u00a0\u00a0<\/p>\n

“Clearly this weakens Novo Nordisk’s competitive stance in the obesity market \u2013 especially if the obesity market develops into a \u2018winner takes it all’ market,” Borsting said, per Zero Hedge.\u00a0<\/p>\n

Borsting added that while Novo’s portfolio remains solid and diversified, the news is undeniably \u201ccredit negative.\u201d<\/p>\n

The Path Forward<\/p>\n

Despite the setback, Novo Nordisk management is looking toward future milestones.\u00a0<\/p>\n

Martin Holst Lange, executive vice president of R&D, remarked: “Based on the learnings from completed studies, we look forward to the REDEFINE 11 readout and the initiation of the higher-dose CagriSema trial, which are both designed to assess the full weight-loss potential of CagriSema.”<\/p>\n

Novo Nordisk has already submitted CagriSema to the FDA for approval based on earlier REDEFINE trials, with a decision expected by late 2026.\u00a0<\/p>\n

However, with the higher-dose trial not slated to begin until late 2026 and REDEFINE 11 results not due until 2027, Novo faces a grueling climb to regain market dominance.<\/p>\n

Photo: Piotr Swat \/ Shutterstock<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk AS (NYSE:NVO), once the darling of the pharmaceutical world, tumbled Monday as investors reacted to what…\n","protected":false},"author":2,"featured_media":22107,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[271],"tags":[2085,8256,2094,2087,14886,2092,2088,2093,2084,272,352,8257,2096,3969,14887,2100],"class_list":{"0":"post-22106","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-novo-nordisk","8":"tag-category-biotech","9":"tag-category-fda","10":"tag-category-general","11":"tag-category-large-cap","12":"tag-category-management","13":"tag-category-movers","14":"tag-category-news","15":"tag-category-trading-ideas","16":"tag-cms-wordpress","17":"tag-novo-nordisk","18":"tag-pageisbzpro-bz","19":"tag-symbol-lly","20":"tag-symbol-nvo","21":"tag-tag-ai-generated","22":"tag-tag-glp-1","23":"tag-tag-why-its-moving"},"share_on_mastodon":{"url":"","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/22106","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/comments?post=22106"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/posts\/22106\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media\/22107"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/media?parent=22106"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/categories?post=22106"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/dk\/wp-json\/wp\/v2\/tags?post=22106"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}